Civic Intelligence

Myelin Repair Foundation Inc

EIN 03-0485196 • 501(c)3 • Saratoga, CA

Profile

The myelin repair foundation grants funds for research to develop rational drug targets to slow, stop, and ultimately repair damage to myelin caused by multiple sclerosis. The foundation has a defined process for collaboration among scientists and with businesses that substantially shortens the time to discovery of the mechanisms for myelin repair as well as the time to commercialize these mechanisms in the form of treatments for ms patients.

20111 Edinburgh DriveSaratoga, CA 95070

www.myelinrepair.org

Siviq Scores

Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.

Liabilities / Assets

86th percentile

0.49x

Higher debt load relative to assets than 86% of similar nonprofits.

501(c)3 • $500k-$1M nonprofits • Source year 2025

Liabilities / Revenue

94th percentile

1.62x

Higher debt load relative to revenue than 94% of similar nonprofits.

501(c)3 • $500k-$1M nonprofits • Source year 2025

Net Margin

4th percentile

-92%

Higher net margin than 4% of similar nonprofits.

501(c)3 • $500k-$1M nonprofits • Source year 2025

Top Officer Pay

91st percentile

$120,000

Higher top officer pay than 91% of similar nonprofits.

Top officer pay equals 44.8% of source-year revenue.

501(c)3 • $500k-$1M nonprofits • Source year 2025

Asset Growth

9th percentile

-32%

Faster asset growth than 9% of similar nonprofits.

501(c)3 • $500k-$1M nonprofits • Annualized from 2024 to 2025

Revenue Growth

40th percentile

0.6%

Faster revenue growth than 40% of similar nonprofits.

501(c)3 • $500k-$1M nonprofits • Annualized from 2024 to 2025

Balance Sheet
Liabilities / Assets86th percentile

Assets

Down

$877,106

Down $418,765 (-32%) from 2024

Liabilities

Down

$433,716

Down $173,545 (-29%) from 2024

Net Assets

Down

$443,390

Down $245,220 (-36%) from 2024

Operations
Liabilities / Revenue94th percentileNet Margin4th percentile

Revenue

Up

$267,774

Up $1,703 (+0.6%) from 2024

Expenses

Up

$512,994

Up $9,290 (+1.8%) from 2024

Net Income

Down

-$245,220

Down $7,587 (-3.2%) from 2024

Trend Graphs

Balance Sheet Trend

Asset Growth9th percentile

Grouped bars show assets, liabilities, and net assets across loaded filings.

$15M$10M$5.0M$0Assets 2011: $12,790,194Liabilities 2011: $698,435Net Assets 2011: $12,091,7592011Assets 2012: $8,436,907Liabilities 2012: $575,288Net Assets 2012: $7,861,6192012Assets 2013: $7,317,764Liabilities 2013: $575,013Net Assets 2013: $6,742,7512013Assets 2014: $4,343,784Liabilities 2014: $405,300Net Assets 2014: $3,938,4842014Assets 2015: $1,355,841Liabilities 2015: $281,806Net Assets 2015: $1,074,0352015Assets 2016: $834,421Liabilities 2016: $115Net Assets 2016: $834,3062016Assets 2017: $840,688Liabilities 2017: $1,160Net Assets 2017: $839,5282017Assets 2018: $1,627,215Liabilities 2018: $299,317Net Assets 2018: $1,327,8982018Assets 2019: $1,552,624Liabilities 2019: $468,441Net Assets 2019: $1,084,1832019Assets 2020: $1,357,117Liabilities 2020: $561,039Net Assets 2020: $796,0782020Assets 2021: $1,468,414Liabilities 2021: $377,528Net Assets 2021: $1,090,8862021Assets 2022: $1,330,627Liabilities 2022: $493,264Net Assets 2022: $837,3632022Assets 2023: $1,550,183Liabilities 2023: $623,940Net Assets 2023: $926,2432023Assets 2024: $1,295,871Liabilities 2024: $607,261Net Assets 2024: $688,6102024Assets 2025: $877,106Liabilities 2025: $433,716Net Assets 2025: $443,3902025

Highlighted filing

2025

Assets$877,106
Liabilities$433,716
Net Assets$443,390
Open 2025 Filing

Operations Trend

Revenue Growth40th percentile

Revenue, expenses, and net income by year, with the latest filing highlighted.

$10M$5.0M$0-$5.0MRevenue 2011: $1,521,887Expenses 2011: $5,374,594Net Income 2011: -$3,852,7072011Revenue 2012: $1,783,057Expenses 2012: $6,013,197Net Income 2012: -$4,230,1402012Revenue 2013: $4,379,557Expenses 2013: $5,498,425Net Income 2013: -$1,118,8682013Revenue 2014: $3,481,896Expenses 2014: $6,286,163Net Income 2014: -$2,804,2672014Revenue 2015: $2,755,891Expenses 2015: $5,624,810Net Income 2015: -$2,868,9192015Revenue 2016: $576,238Expenses 2016: $814,056Net Income 2016: -$237,8182016Revenue 2017: $65,000Expenses 2017: $183,135Net Income 2017: -$118,1352017Revenue 2018: $1,077,554Expenses 2018: $589,184Net Income 2018: $488,3702018Revenue 2019: $294,685Expenses 2019: $538,400Net Income 2019: -$243,7152019Revenue 2020: $266,648Expenses 2020: $554,753Net Income 2020: -$288,1052020Revenue 2021: $530,327Expenses 2021: $235,519Net Income 2021: $294,8082021Revenue 2022: $285,427Expenses 2022: $538,950Net Income 2022: -$253,5232022Revenue 2023: $552,239Expenses 2023: $463,359Net Income 2023: $88,8802023Revenue 2024: $266,071Expenses 2024: $503,704Net Income 2024: -$237,6332024Revenue 2025: $267,774Expenses 2025: $512,994Net Income 2025: -$245,2202025

Highlighted filing

2025

Revenue$267,774
Expenses$512,994
Net Income-$245,220
Open 2025 Filing

Filings

Most recent year

2025 • Form 990Facts available. Structured filing facts are available, but richer extracted sections are limited.

Open filing
Assets
$877,106
Liabilities
$433,716
Net assets
$443,390
Revenue
$267,774
Expenses
$512,994
Net income
-$245,220
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2025Facts available. Structured filing facts are available, but richer extracted sections are limited.$0.88$0.43$0.44$0.27$0.51$0.25
2024Detailed filing. Detailed filing data is available for this year.$1.30$0.61$0.69$0.27$0.50$0.24
2023Facts available. Structured filing facts are available, but richer extracted sections are limited.$1.55$0.62$0.93$0.55$0.46$0.09
2022XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$1.33$0.49$0.84$0.29$0.54$0.25
2021XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$1.47$0.38$1.09$0.53$0.24$0.29
2020XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$1.36$0.56$0.80$0.27$0.55$0.29
2019Detailed filing. Detailed filing data is available for this year.$1.55$0.47$1.08$0.29$0.54$0.24
2018XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$1.63$0.30$1.33$1.08$0.59$0.49
2017Detailed filing. Detailed filing data is available for this year.$0.84$0.00$0.84$0.07$0.18$0.12
2016XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$0.83$0.00$0.83$0.58$0.81$0.24
2015Detailed filing. Detailed filing data is available for this year.$1.36$0.28$1.07$2.76$5.62$2.87
2014Detailed filing. Detailed filing data is available for this year.$4.34$0.41$3.94$3.48$6.29$2.80
2013Facts available. Structured filing facts are available, but richer extracted sections are limited.$7.32$0.58$6.74$4.38$5.50$1.12
2012Summary only. Only limited summary data is available for this year.$8.44$0.58$7.86$1.78$6.01$4.23
2011Summary only. Only limited summary data is available for this year.$12.8$0.70$12.1$1.52$5.37$3.85
Latest Filing Detail
Jump To
Filing Snapshot
Filing Period
Jul 1, 2024 to Jun 30, 2025
Signed
Nov 6, 2025
Return Version
2024v5.0
Gross Receipts
$267,774
Mission and Program Overview

Mission

To accelerate the development of new therapeutics to prevent or repair damage to myelin caused by multiple sclerosis. The mrf is helping to identify biomarkers of myelin repair for use in myelin repair drug development and clinical trials.

Accelerating the development of new therapeutics to prevent or repair damage to myelin caused by Multiple Sclerosis. Myelin Repair Foundation is helping to identify biomarkers of myelin repair for use in myelin repair drug development and clinical trials

Balance Sheet Detail
LineBeginningEndChange
Assets
Savings and Temporary Cash Investments$1,054,139$818,937▼ $235,202
Pledges and Grants Receivable$143,000$35,000▼ $108,000
Cash and Non-Interest-Bearing Accounts$84,313$15,535▼ $68,778
Accounts Receivable$14,419$7,634▼ $6,785
Total Assets$1,295,871$877,106▼ $418,765
Liabilities
Accounts Payable and Accrued Expenses$607,261$433,716▼ $173,545
Total Liabilities$607,261$433,716▼ $173,545
Net Assets / Fund Balance
Net Assets Without Donor Restrictions$688,610$443,390▼ $245,220
Net Assets With Donor Restrictions$0$0→ $0
Total Net Assets Fund Balance$688,610$443,390▼ $245,220
Total Liabilities and Net Assets / Fund Balance$1,295,871$877,106▼ $418,765
Compensation and Service Providers
Top Officer Pay91st percentile

Employees

NameTitleFull / Part TimeBaseTotal
Scott JohnsonCEOPT$120,000$120,000

Board Members and Trustees

NameTitle
Andy CatesDirector
Bobby MehtaDirector
Eric HsuDirector
Jim GidwitzDirector

Highest Paid Contractors

ContractorServicesLocationCompensation
Susan GoelzAnalysis of Scientific Research Agreement Results6900 SE 35th Avenue, Portland, OR 97202$127,157
Revenue and Support

Revenue Composition

Contributions and Grants
$167,240
Program Service Revenue
$0
Investment Income
$37,734
Other Revenue
$62,800
All Other Contributions
$167,240
Change in Net Assets
$-245,220
Expenses and Functional Allocation

Major Expense Lines

Line ItemAmount
Grants and Similar Amounts Paid$208,000
Other Expenses$158,012
Salaries, Compensation, and Employee Benefits$146,982
Total Fundraising Expense$14,358
Professional Fundraising Fees$0

Functional Expense Allocation

Line ItemProgramManagementFundraisingTotal
Fees for Services Other$137,657--$137,657
Current Officers, Directors, Trustees, and Key Employees$103,200$6,000$10,800$120,000
Foreign Grants$108,000--$108,000
Grants to Domestic Orgs$100,000--$100,000
Other Employee Benefits$14,936$868$1,564$17,368
Office Expenses$10,789$627$1,129$12,545
Payroll Taxes$8,268$481$865$9,614
Fees for Services Accounting-$5,020-$5,020
Insurance$2,790--$2,790
Total Functional Expenses$485,640$12,996$14,358$512,994
International Activity

Grant and Assistance Recipients

RecipientLocationCategoryPurposeAmount
Yale UniversityNew Haven, CT-There are two scientific research agreements with Yale for $50,000 each. The first is to validate the exosomal small RNA biomarker for MS progression in an additional validation cohort, consisting of 40 progressive and stable MS patients and then confirm the astrocyte origin of progression-associated RNAs by verifying their expression or downregulation in reactive astrocytes in autopsied brain tissue from progressive MS patients. Lastly, to test whether GLAST+ exosomes from progressive but not stable MS patients or healthy controls induce proinflammatory pathways in human iPSC-derived microglial cells that are also active in microglial populations in the brain of progressive MS patients. The second SRA aims to Develop a robust protocol to isolate OL-derived exosomes and quantify their lipid and protein content and determine the small RNA, lipid and proteomic signatures in oligodendrocyte-exosomes correlated to remyelination using samples from the RENEW optic neuritis treatment trial.$100,000

International Summary

Offices
0
Employees
0
Spending
$108,000

International Compliance

Foreign grant records maintained
Yes
Activity in boycott countries
No
Foreign corporation ownership
No
Foreign partnership interest
No
Interest in foreign trust
No
Passive foreign investment company interest
No
Transfers to foreign corporations
No

International Activities

RegionActivityServicesOfficesEmployeesSpending
Europe (including Iceland and Greenland)Program ServicesThe overall objective of this project is to develop an analytical pipeline to assess the cargo of EVs found in the serum and secreted by neurons, astrocytes and oligodendrocytes. This pipeline will then be used to identify a blood-derived signature of MS. Extracellular vesicles offer a promising avenue for the discovery of biomarkers to help tackle multiple sclerosis progression. By analyzing the cargo of EVs, we hope to obtain valuable insights on neuroinflammation, neurodegeneration, and treatment response. As the field advances and standardization efforts progress, EV-based biomarkers may revolutionize disease monitoring, personalized treatment approaches, and the development of novel therapeutics ultimately leading to improved outcomes for patients with multiple sclerosis.00$108,000
Fundraising, Events, and Gaming
Fundraising activities
No
Gaming activities
No
Professional fundraiser used
No

Fundraising and Gaming Totals

Line ItemAmount
Professional Fundraising Fees$0
Political and Lobbying Activity
Political campaign activity
No
Lobbying activity
No
Subject to proxy tax
No
Governance and Compliance

Governance Checklist

Compiled or reviewed by an accountant
No
Annual disclosure for covered persons
Yes
Backup withholding compliance
Yes
Business relationship with 35% controlled entity
No
Business relationship with family members
No
Business relationship with organization members
No
Material changes to governing documents
No
Compensation from other sources disclosed
No
CEO compensation reviewed
Yes
Other officer compensation reviewed
No
Conflict-of-interest policy
Yes
Audited financial statements prepared
No
Key decisions subject to board approval
No
Management duties delegated
No

Governance Explanations

Form 990, Part VI, Section A, Line 9

“Andy Cates-429N Main Street,suite 100, Memphis, TN 38103; Jim Gidwitz -440 S LaSalle, suite 3100, Chicago IL 60605; Bobby Mehta-159 E Walton Street Chicago IL 60611; Eric Hsu-650 Page Mill Road Palo Alto CA 94304-1050”

Form 990, Part VI, Section B, Line 11B

“Form 990 is reviewed by the CEO, and once the CEO approves, it is then forwarded to the board members for their review prior to filing. Board members are encouraged to review and forward their questions, if any, to the CEO.”

Form 990, Part VI, Section B, Line 12C

“Officers, directors, and key employees are covered. Any and all conflicts are reviewed by disinterested board members and if needed by legal counsel. Persons with a conflict of interest will be restricted from making any key decisions for MRF as they relate to the interest, unless otherwise approved by the majority of the disinterested parties”

Form 990, Part VI, Section B, Line 15

“Compensation is determined by the Board of Directors”

Form 990, Part VI, Section C, Line 19

“Financial Statements, governing documents, and policies are available upon request.”

Filing and Contact Details

Filer

Filer Name
Myelin Repair Foundation Inc
EIN
03-0485196
Address
20111 Edinburgh Drive, Saratoga, CA 95070

Signing Officer

Name
Scott Johnson
Title
Chief Executive Officer
Phone
4087610201
Signed
2025-11-06

Organization Details

Principal Officer
Scott Johnson
Formed
2002
Legal Domicile
CA
Voting Board Members
5
Independent Board Members
4
Employees
1
Volunteers
0
Supplemental Narrative

Additional Explanations

Form 990, Part IX, Line 11G

“General Consulting”

Raw XML AppendixShowing 400 of 427 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990/AccountantCompileOrReviewInd00
IRS990/AccountsPayableAccrExpnssGrp/BOYAmt0607261
IRS990/AccountsPayableAccrExpnssGrp/EOYAmt0433716
IRS990/AccountsReceivableGrp/BOYAmt014419
IRS990/AccountsReceivableGrp/EOYAmt07634
IRS990/ActivitiesConductedPrtshpInd00
IRS990/ActivityOrMissionDesc0Accelerating the development of new therapeutics to prevent or repair damage to myelin caused by Multiple Sclerosis. Myelin Repair Foundation is helping to identify biomarkers of myelin repair for use in myelin repair drug development and clinical trials
IRS990/AllOtherContributionsAmt0167240
IRS990/AnnualDisclosureCoveredPrsnInd01
IRS990/BackupWthldComplianceInd01
IRS990/BooksInCareOfDetail/PersonNm0Louise Savoie
IRS990/BooksInCareOfDetail/PhoneNum04088885542
IRS990/BooksInCareOfDetail/USAddress/AddressLine1Txt02198 Hillstone Dr
IRS990/BooksInCareOfDetail/USAddress/CityNm0San Jose
IRS990/BooksInCareOfDetail/USAddress/StateAbbreviationCd0CA
IRS990/BooksInCareOfDetail/USAddress/ZIPCd095138
IRS990/BusinessRlnWith35CtrlEntInd00
IRS990/BusinessRlnWithFamMemInd00
IRS990/BusinessRlnWithOrgMemInd00
IRS990/CashNonInterestBearingGrp/BOYAmt084313
IRS990/CashNonInterestBearingGrp/EOYAmt015535
IRS990/ChangeToOrgDocumentsInd00
IRS990/CntrctRcvdGreaterThan100KCnt01
IRS990/CollectionsOfArtInd00
IRS990/CompCurrentOfcrDirectorsGrp/FundraisingAmt010800
IRS990/CompCurrentOfcrDirectorsGrp/ManagementAndGeneralAmt06000
IRS990/CompCurrentOfcrDirectorsGrp/ProgramServicesAmt0103200
IRS990/CompCurrentOfcrDirectorsGrp/TotalAmt0120000
IRS990/CompensationFromOtherSrcsInd00
IRS990/CompensationProcessCEOInd01
IRS990/CompensationProcessOtherInd00
IRS990/ConflictOfInterestPolicyInd01
IRS990/ConservationEasementsInd00
IRS990/ConsolidatedAuditFinclStmtInd00
IRS990/ContractorCompensationGrp/CompensationAmt0127157
IRS990/ContractorCompensationGrp/ContractorAddress/USAddress/AddressLine1Txt06900 SE 35th Avenue
IRS990/ContractorCompensationGrp/ContractorAddress/USAddress/CityNm0Portland
IRS990/ContractorCompensationGrp/ContractorAddress/USAddress/StateAbbreviationCd0OR
IRS990/ContractorCompensationGrp/ContractorAddress/USAddress/ZIPCd097202
IRS990/ContractorCompensationGrp/ContractorName/PersonNm0Susan Goelz
IRS990/ContractorCompensationGrp/ServicesDesc0Analysis of Scientific Research Agreement Results
IRS990/ContriRptFundraisingEventAmt00
IRS990/CreditCounselingInd00
IRS990/CYBenefitsPaidToMembersAmt00
IRS990/CYContributionsGrantsAmt0167240
IRS990/CYGrantsAndSimilarPaidAmt0208000
IRS990/CYInvestmentIncomeAmt037734
IRS990/CYOtherExpensesAmt0158012
IRS990/CYOtherRevenueAmt062800
IRS990/CYProgramServiceRevenueAmt00
IRS990/CYRevenuesLessExpensesAmt0-245220
IRS990/CYSalariesCompEmpBnftPaidAmt0146982
IRS990/CYTotalExpensesAmt0512994
IRS990/CYTotalFundraisingExpenseAmt014358
IRS990/CYTotalProfFndrsngExpnsAmt00
IRS990/CYTotalRevenueAmt0267774
IRS990/DecisionsSubjectToApprovaInd00
IRS990/DeductibleArtContributionInd00
IRS990/DeductibleNonCashContriInd00
IRS990/DelegationOfMgmtDutiesInd00
IRS990/Desc0We only have one area of program services and that is scientific research to benefit Multiple Sclerosis (MS) patients. Currently our research is focused on experiments to identify biomarkers to indicate repair of myelin damaged by MS. Over the last year, we focused our research on extracellular vesicles(EVs) isolated from blood. We currently have 8 investigations underway spread across Europe and North America. We have encouraging preliminary data showing that we can clearly distinguish MS patient EV's from healthy controls and may be able to identify sub-types of MS.
IRS990/DescribedInSection501c3Ind01
IRS990/DisregardedEntityInd00
IRS990/DocumentRetentionPolicyInd01
IRS990/DonatedServicesAndUseFcltsAmt00
IRS990/DonorAdvisedFundInd00
IRS990/DonorRestrictionNetAssetsGrp/BOYAmt00
IRS990/DonorRestrictionNetAssetsGrp/EOYAmt00
IRS990/DonorRstrOrQuasiEndowmentsInd00
IRS990/ElectionOfBoardMembersInd00
IRS990/EmployeeCnt01
IRS990/EmploymentTaxReturnsFiledInd01
IRS990/EngagedInExcessBenefitTransInd00
IRS990/ExpenseAmt0485640
IRS990/FamilyOrBusinessRlnInd00
IRS990/FederalGrantAuditRequiredInd00
IRS990/FederatedCampaignsAmt00
IRS990/FeesForServicesAccountingGrp/ManagementAndGeneralAmt05020
IRS990/FeesForServicesAccountingGrp/TotalAmt05020
IRS990/FeesForServicesOtherGrp/ProgramServicesAmt0137657
IRS990/FeesForServicesOtherGrp/TotalAmt0137657
IRS990/ForeignActivitiesInd01
IRS990/ForeignFinancialAccountInd00
IRS990/ForeignGrantsGrp/ProgramServicesAmt0108000
IRS990/ForeignGrantsGrp/TotalAmt0108000
IRS990/ForeignOfficeInd01
IRS990/Form8282PropertyDisposedOfInd00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt10
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt20
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt30
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt020
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt11
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt21
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt31
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt41
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd0X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd1X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd2X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd3X
IRS990/Form990PartVIISectionAGrp/OfficerInd0X
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt00
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt10
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt20
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt30
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt40
IRS990/Form990PartVIISectionAGrp/PersonNm0Scott Johnson
IRS990/Form990PartVIISectionAGrp/PersonNm1Andy Cates
IRS990/Form990PartVIISectionAGrp/PersonNm2Bobby Mehta
IRS990/Form990PartVIISectionAGrp/PersonNm3Jim Gidwitz
IRS990/Form990PartVIISectionAGrp/PersonNm4Eric Hsu
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt0120000
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt10
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt20
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt30
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt40
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt00
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt10
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt20
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt30
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt40
IRS990/Form990PartVIISectionAGrp/TitleTxt0CEO
IRS990/Form990PartVIISectionAGrp/TitleTxt1Director
IRS990/Form990PartVIISectionAGrp/TitleTxt2Director
IRS990/Form990PartVIISectionAGrp/TitleTxt3Director
IRS990/Form990PartVIISectionAGrp/TitleTxt4Director
IRS990/Form990ProvidedToGvrnBodyInd01
IRS990/FormationYr02002
IRS990/FormerOfcrEmployeesListedInd00
IRS990/FSAuditedInd00
IRS990/FundraisingActivitiesInd00
IRS990/FundraisingAmt00
IRS990/GainOrLossGrp/OtherAmt00
IRS990/GainOrLossGrp/SecuritiesAmt00
IRS990/GamingActivitiesInd00
IRS990/GoverningBodyVotingMembersCnt05
IRS990/GovernmentGrantsAmt00
IRS990/GrantAmt0208000
IRS990/GrantsToDomesticIndividualsGrp/ProgramServicesAmt00
IRS990/GrantsToDomesticIndividualsGrp/TotalAmt00
IRS990/GrantsToDomesticOrgsGrp/ProgramServicesAmt0100000
IRS990/GrantsToDomesticOrgsGrp/TotalAmt0100000
IRS990/GrantsToIndividualsInd00
IRS990/GrantsToOrganizationsInd01
IRS990/GrantToRelatedPersonInd00
IRS990/GrossReceiptsAmt0267774
IRS990/GroupReturnForAffiliatesInd00
IRS990/IncludeFIN48FootnoteInd00
IRS990/IncmFromInvestBondProceedsGrp/ExclusionAmt00
IRS990/IncmFromInvestBondProceedsGrp/RelatedOrExemptFuncIncomeAmt00
IRS990/IncmFromInvestBondProceedsGrp/TotalRevenueColumnAmt00
IRS990/IncmFromInvestBondProceedsGrp/UnrelatedBusinessRevenueAmt00
IRS990/IndependentAuditFinclStmtInd00
IRS990/IndependentVotingMemberCnt04
IRS990/IndivRcvdGreaterThan100KCnt01
IRS990/IndoorTanningServicesInd00
IRS990/InfoInScheduleOPartIXInd0X
IRS990/InfoInScheduleOPartVIInd0X
IRS990/InsuranceGrp/ProgramServicesAmt02790
IRS990/InsuranceGrp/TotalAmt02790
IRS990/InvestmentExpenseAmt00
IRS990/InvestmentIncomeGrp/ExclusionAmt00
IRS990/InvestmentIncomeGrp/RelatedOrExemptFuncIncomeAmt037734
IRS990/InvestmentIncomeGrp/TotalRevenueColumnAmt037734
IRS990/InvestmentIncomeGrp/UnrelatedBusinessRevenueAmt00
IRS990/InvestmentInJointVentureInd00
IRS990/IRPDocumentCnt05
IRS990/IRPDocumentW2GCnt00
IRS990/LegalDomicileStateCd0CA
IRS990/LoanOutstandingInd00
IRS990/LobbyingActivitiesInd00
IRS990/LocalChaptersInd00
IRS990/MaterialDiversionOrMisuseInd00
IRS990/MembershipDuesAmt00
IRS990/MembersOrStockholdersInd00
IRS990/MethodOfAccountingAccrualInd0X
IRS990/MinutesOfCommitteesInd01
IRS990/MinutesOfGoverningBodyInd01
IRS990/MiscellaneousRevenueGrp/ExclusionAmt00
IRS990/MiscellaneousRevenueGrp/RelatedOrExemptFuncIncomeAmt062800
IRS990/MiscellaneousRevenueGrp/TotalRevenueColumnAmt062800
IRS990/MiscellaneousRevenueGrp/UnrelatedBusinessRevenueAmt00
IRS990/MissionDesc0Accelerating the development of new therapeutics to prevent or repair damage to myelin caused by Multiple Sclerosis. The MRF is helping to identify biomarkers of myelin repair for use in myelin repair drug development and clinical trials
IRS990/MoreThan5000KToIndividualsInd00
IRS990/MoreThan5000KToOrgInd01
IRS990/NetAssetsOrFundBalancesBOYAmt0688610
IRS990/NetAssetsOrFundBalancesEOYAmt0443390
IRS990/NetUnrelatedBusTxblIncmAmt00
IRS990/NetUnrlzdGainsLossesInvstAmt00
IRS990/NoDonorRestrictionNetAssetsGrp/BOYAmt0688610
IRS990/NoDonorRestrictionNetAssetsGrp/EOYAmt0443390
IRS990/NoncashContributionsAmt00
IRS990/NondeductibleContributionsInd00
IRS990/OfficeExpensesGrp/FundraisingAmt01129
IRS990/OfficeExpensesGrp/ManagementAndGeneralAmt0627
IRS990/OfficeExpensesGrp/ProgramServicesAmt010789
IRS990/OfficeExpensesGrp/TotalAmt012545
IRS990/OfficerMailingAddressInd01
IRS990/OperateHospitalInd00
IRS990/Organization501c3Ind0X
IRS990/OrganizationFollowsFASB117Ind0X
IRS990/OtherChangesInNetAssetsAmt00
IRS990/OtherEmployeeBenefitsGrp/FundraisingAmt01564
IRS990/OtherEmployeeBenefitsGrp/ManagementAndGeneralAmt0868
IRS990/OtherEmployeeBenefitsGrp/ProgramServicesAmt014936
IRS990/OtherEmployeeBenefitsGrp/TotalAmt017368
IRS990/OtherRevenueTotalAmt062800
IRS990/PartialLiquidationInd00
IRS990/PayPremiumsPrsnlBnftCntrctInd00
IRS990/PayrollTaxesGrp/FundraisingAmt0865
IRS990/PayrollTaxesGrp/ManagementAndGeneralAmt0481
IRS990/PayrollTaxesGrp/ProgramServicesAmt08268
IRS990/PayrollTaxesGrp/TotalAmt09614
IRS990/PledgesAndGrantsReceivableGrp/BOYAmt0143000
IRS990/PledgesAndGrantsReceivableGrp/EOYAmt035000
IRS990/PoliticalCampaignActyInd00
IRS990/PrincipalOfficerNm0Scott Johnson
IRS990/PriorPeriodAdjustmentsAmt00
IRS990/ProfessionalFundraisingInd00
IRS990/ProhibitedTaxShelterTransInd00
IRS990/PYBenefitsPaidToMembersAmt00
IRS990/PYContributionsGrantsAmt0201187
IRS990/PYExcessBenefitTransInd00
IRS990/PYGrantsAndSimilarPaidAmt0310296
IRS990/PYInvestmentIncomeAmt052232
IRS990/PYOtherExpensesAmt050130
IRS990/PYOtherRevenueAmt012652
IRS990/PYProgramServiceRevenueAmt00
IRS990/PYRevenuesLessExpensesAmt0-237633
IRS990/PYSalariesCompEmpBnftPaidAmt0143278
IRS990/PYTotalExpensesAmt0503704
IRS990/PYTotalProfFndrsngExpnsAmt00
IRS990/PYTotalRevenueAmt0266071
IRS990/QuidProQuoContributionsInd00
IRS990/RcvFndsToPayPrsnlBnftCntrctInd00
IRS990/ReconcilationRevenueExpnssAmt0-245220
IRS990/RegularMonitoringEnfrcInd01
IRS990/RelatedEntityInd00
IRS990/RelatedOrganizationCtrlEntInd00
IRS990/RelatedOrganizationsAmt00
IRS990/RentalIncomeOrLossGrp/PersonalAmt00
IRS990/RentalIncomeOrLossGrp/RealAmt00
IRS990/ReportInvestmentsOtherSecInd00
IRS990/ReportLandBuildingEquipmentInd00
IRS990/ReportOtherAssetsInd00
IRS990/ReportOtherLiabilitiesInd00
IRS990/ReportProgramRelatedInvstInd00
IRS990/RevenueAmt0268148
IRS990/RoyaltiesRevenueGrp/ExclusionAmt00
IRS990/RoyaltiesRevenueGrp/RelatedOrExemptFuncIncomeAmt00
IRS990/RoyaltiesRevenueGrp/TotalRevenueColumnAmt00
IRS990/RoyaltiesRevenueGrp/UnrelatedBusinessRevenueAmt00
IRS990/SavingsAndTempCashInvstGrp/BOYAmt01054139
IRS990/SavingsAndTempCashInvstGrp/EOYAmt0818937
IRS990ScheduleA/Form990ScheduleAPartVIGrp/ExplanationTxt0Unused Scientific Research Agreement Funds. On occasion, SRAs use less than the amount granted.
IRS990ScheduleA/Form990ScheduleAPartVIGrp/FormAndLineReferenceDesc0Schedule A, Part II, Line 10
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt0167240
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt0201187
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt0527737
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt0262804
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus4YearsAmt0478580
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt01637548
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus1YearAmt052232
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus2YearsAmt031061
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus3YearsAmt0914
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus4YearsAmt0699
IRS990ScheduleA/GrossInvestmentIncome170Grp/TotalAmt084906
IRS990ScheduleA/OtherIncome170Grp/CurrentTaxYearAmt062800
IRS990ScheduleA/OtherIncome170Grp/CurrentTaxYearMinus1YearAmt012652
IRS990ScheduleA/OtherIncome170Grp/CurrentTaxYearMinus2YearsAmt00
IRS990ScheduleA/OtherIncome170Grp/CurrentTaxYearMinus3YearsAmt021709
IRS990ScheduleA/OtherIncome170Grp/CurrentTaxYearMinus4YearsAmt051048
IRS990ScheduleA/OtherIncome170Grp/TotalAmt0148209
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportCY170Pct00.42677
IRS990ScheduleA/PublicSupportPY170Pct00.49498
IRS990ScheduleA/PublicSupportTotal170Amt0798345
IRS990ScheduleA/SubstantialContributorsTotAmt0839203
IRS990ScheduleA/ThirtyThrPctSuprtTestsCY170Ind0X
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt0167240
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt0201187
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt0527737
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt0262804
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt0478580
IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt01637548
IRS990ScheduleA/TotalSupportAmt01870663
IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorNum0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine20RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt0RESTRICTED
IRS990/ScheduleBRequiredInd01
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt00
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt00
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt0108000
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt0Europe (including Iceland and Greenland)
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt0The overall objective of this project is to develop an analytical pipeline to assess the cargo of EVs found in the serum and secreted by neurons, astrocytes and oligodendrocytes. This pipeline will then be used to identify a blood-derived signature of MS. Extracellular vesicles offer a promising avenue for the discovery of biomarkers to help tackle multiple sclerosis progression. By analyzing the cargo of EVs, we hope to obtain valuable insights on neuroinflammation, neurodegeneration, and treatment response. As the field advances and standardization efforts progress, EV-based biomarkers may revolutionize disease monitoring, personalized treatment approaches, and the development of novel therapeutics ultimately leading to improved outcomes for patients with multiple sclerosis.
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt0Program Services
IRS990ScheduleF/BoycottCountriesInd00
IRS990ScheduleF/ForeignCorpOwnershipInd00
IRS990ScheduleF/ForeignPartnershipInd00
IRS990ScheduleF/GrantRecordsMaintainedInd01
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt0108000
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt0cash progress payments
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/NonCashAssistanceAmt00
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt0Scientific research
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt0Europe (including Iceland and Greenland)
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/ValuationMethodUsedDesc0contractual amount
IRS990ScheduleF/InterestInForeignTrustInd00
IRS990ScheduleF/PassiveForeignInvestmestCoInd00
IRS990ScheduleF/SupplementalInformationDetail/ExplanationTxt0Grants outside the United States are treated the same as grants within the United States with regular required reports and conversations with recipients
IRS990ScheduleF/SupplementalInformationDetail/FormAndLineReferenceDesc0Schedule F, Part I, Line 2
IRS990ScheduleF/Total501c3OrgCnt00
IRS990ScheduleF/TotalEmployeeCnt00
IRS990ScheduleF/TotalOfficeCnt00
IRS990ScheduleF/TotalOtherOrgCnt01
IRS990ScheduleF/TotalSpentAmt0108000
IRS990ScheduleF/TransferToForeignCorpInd00
IRS990ScheduleI/GrantRecordsMaintainedInd01
IRS990ScheduleI/RecipientTable/CashGrantAmt0100000
IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt00
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt0There are two scientific research agreements with Yale for $50,000 each. The first is to validate the exosomal small RNA biomarker for MS progression in an additional validation cohort, consisting of 40 progressive and stable MS patients and then confirm the astrocyte origin of progression-associated RNAs by verifying their expression or downregulation in reactive astrocytes in autopsied brain tissue from progressive MS patients. Lastly, to test whether GLAST+ exosomes from progressive but not stable MS patients or healthy controls induce proinflammatory pathways in human iPSC-derived microglial cells that are also active in microglial populations in the brain of progressive MS patients. The second SRA aims to Develop a robust protocol to isolate OL-derived exosomes and quantify their lipid and protein content and determine the small RNA, lipid and proteomic signatures in oligodendrocyte-exosomes correlated to remyelination using samples from the RENEW optic neuritis treatment trial.
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt0Yale University
IRS990ScheduleI/RecipientTable/RecipientEIN0060646973
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt025 Science Park 150 Munson St
IRS990ScheduleI/RecipientTable/USAddress/CityNm0New Haven
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd0CT
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd006520
IRS990ScheduleI/RecipientTable/ValuationMethodUsedDesc0contractual amount
IRS990ScheduleI/SupplementalInformationDetail/ExplanationTxt0The recipients are subject to the terms and conditions of the sponsored research agreement between them and MRF. The researcher's work is reviewed by the MRF Scientific Director, the Executive Committee, and the MRF president.
IRS990ScheduleI/SupplementalInformationDetail/FormAndLineReferenceDesc0Schedule I, Part I, Line 2
IRS990ScheduleI/Total501c3OrgCnt01
IRS990ScheduleI/TotalOtherOrgCnt00
IRS990/ScheduleJRequiredInd00
IRS990/ScheduleORequiredInd01
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0Andy Cates-429N Main Street,suite 100, Memphis, TN 38103; Jim Gidwitz -440 S LaSalle, suite 3100, Chicago IL 60605; Bobby Mehta-159 E Walton Street Chicago IL 60611; Eric Hsu-650 Page Mill Road Palo Alto CA 94304-1050
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1Form 990 is reviewed by the CEO, and once the CEO approves, it is then forwarded to the board members for their review prior to filing. Board members are encouraged to review and forward their questions, if any, to the CEO.
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt2Officers, directors, and key employees are covered. Any and all conflicts are reviewed by disinterested board members and if needed by legal counsel. Persons with a conflict of interest will be restricted from making any key decisions for MRF as they relate to the interest, unless otherwise approved by the majority of the disinterested parties
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt3Compensation is determined by the Board of Directors
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt4Financial Statements, governing documents, and policies are available upon request.
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt5General Consulting
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0Form 990, Part VI, Section A, Line 9
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1Form 990, Part VI, Section B, Line 11b
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc2Form 990, Part VI, Section B, Line 12c
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc3Form 990, Part VI, Section B, Line 15
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc4Form 990, Part VI, Section C, Line 19
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc5Form 990, Part IX, Line 11g
IRS990/SchoolOperatingInd00
IRS990/SignificantChangeInd00
IRS990/SignificantNewProgramSrvcInd00
IRS990/StatesWhereCopyOfReturnIsFldCd0CA
IRS990/SubjectToExcsTaxNetInvstIncInd00
IRS990/SubjectToProxyTaxInd00
IRS990/SubjToTaxRmnrtnExPrchtPymtInd00
IRS990/TaxablePartyNotificationInd00
IRS990/TaxExemptBondsInd00
IRS990/TerminateOperationsInd00
IRS990/TotalAssetsBOYAmt01295871
IRS990/TotalAssetsEOYAmt0877106
IRS990/TotalAssetsGrp/BOYAmt01295871
IRS990/TotalAssetsGrp/EOYAmt0877106
IRS990/TotalCompGreaterThan150KInd00
IRS990/TotalContributionsAmt0167240
IRS990/TotalEmployeeCnt01
IRS990/TotalFunctionalExpensesGrp/FundraisingAmt014358
IRS990/TotalFunctionalExpensesGrp/ManagementAndGeneralAmt012996
IRS990/TotalFunctionalExpensesGrp/ProgramServicesAmt0485640
IRS990/TotalFunctionalExpensesGrp/TotalAmt0512994
IRS990/TotalGrossUBIAmt00
IRS990/TotalLiabilitiesBOYAmt0607261
IRS990/TotalLiabilitiesEOYAmt0433716
IRS990/TotalLiabilitiesGrp/BOYAmt0607261
IRS990/TotalLiabilitiesGrp/EOYAmt0433716
IRS990/TotalNetAssetsFundBalanceGrp/BOYAmt0688610
IRS990/TotalNetAssetsFundBalanceGrp/EOYAmt0443390
IRS990/TotalOtherCompensationAmt00
IRS990/TotalOtherProgSrvcExpenseAmt00
IRS990/TotalOtherProgSrvcGrantAmt00
IRS990/TotalOtherProgSrvcRevenueAmt00
IRS990/TotalOthProgramServiceRevGrp/ExclusionAmt00
IRS990/TotalOthProgramServiceRevGrp/RelatedOrExemptFuncIncomeAmt00
IRS990/TotalOthProgramServiceRevGrp/TotalRevenueColumnAmt00
IRS990/TotalOthProgramServiceRevGrp/UnrelatedBusinessRevenueAmt00
IRS990/TotalProgramServiceExpensesAmt0485640
IRS990/TotalProgramServiceRevenueAmt00
IRS990/TotalReportableCompFromOrgAmt0120000
IRS990/TotalRevenueGrp/ExclusionAmt00
IRS990/TotalRevenueGrp/RelatedOrExemptFuncIncomeAmt0100534
IRS990/TotalRevenueGrp/TotalRevenueColumnAmt0267774
IRS990/TotalRevenueGrp/UnrelatedBusinessRevenueAmt00
IRS990/TotalVolunteersCnt00
IRS990/TotLiabNetAssetsFundBalanceGrp/BOYAmt01295871
IRS990/TotLiabNetAssetsFundBalanceGrp/EOYAmt0877106
IRS990/TotReportableCompRltdOrgAmt00
IRS990/TrnsfrExmptNonChrtblRltdOrgInd00
IRS990/TypeOfOrganizationCorpInd0X
IRS990/UnrelatedBusIncmOverLimitInd00

Document Assets

No mirrored PDF or thumbnail assets are attached yet.